OncoTricks

Look before you treat: a marrow, a scalp, a node, Oct 22, 2026

Refractory immune thrombocytopenia (ITP): the marrow before the pill

A man has carried a diagnosis of immune thrombocytopenia for twenty years. Steroids, immunoglobulin, rituximab, splenectomy. Platelets sit under 30 (thousands) and he has never bled. A thrombopoietin agonist is prescribed. Then a flow cytometry report mentions monocytosis and eosinophilia.

If you remember one thingA refractory patient who is not bleeding has time. Spend it on the bone marrow, before the agonist changes what the pathologist will see.

Concepts first

WHAT THE WORDS MEAN Immune thrombocytopenia platelets under 100 thousand and no other cause found an antibody clears platelets and slows their production; no test proves it (Rodeghiero) The three phases new: under 3 months persistent: 3 to 12 months chronic: over 12 months most adults do not remit alone Refractory failed splenectomy and still needs treatment (Rodeghiero 2009) now also used for failure of several drug lines: the moment to doubt the diagnosis (Miltiadous) THE FOUR NAMES IN THIS CASE TPO agonists TPO is thrombopoietin;these drugs mimic it:eltrombopag andavatrombopag (pills),romiplostim (weekly shot) Monocytosis monocytes 0.5 or more(thousands) and 10% ormore of white cells,persisting CMML chronic myelomonocyticleukemia: monocytosisplus dysplasia and/or aclone (both if monocytesunder 1); blasts < 20% Reticulin the fiber scaffold ofthe marrow, graded0 to 3; more fibermeans a stressed marrow

Why the marrow comes first

MARROW BEFORE a few megakaryocytes, little fiber readable: immune, or something else TPO agonist weeks MARROW AFTER many large megakaryocytes, more fiber read as "megakaryocytic hyperplasia" Fibrosis on the drug is rare romiplostim: reticulin reported in 10 of 271 trial patients, often falling after the drug stopped (Kuter 2009) eltrombopag: 117 patients, 232 biopsies over up to 5.5 years, moderate to marked fibrosis in 2 (Brynes 2015)

TPO thrombopoietin, the hormone that drives platelet production · megakaryocyte the marrow cell that sheds platelets · flow cytometry counts and types blood cells by surface markers; it flagged the monocytes here

The drug is safe for the marrow. The problem is reading the marrow after it.The marrow is not routine in immune thrombocytopenia: with a typical presentation it is not needed at any age (Neunert 2011). Do it for an abnormality in another lineage or on the smear (monocytosis and eosinophilia count), for no response to first-line therapy, for relapse after remission, or before splenectomy (Provan 2019). This man ticks two.

Decide in clinic

1. Bleeding now, or a count under 10 to 20 with a reason to fear bleeding?
yes
Treat today, marrow laterSteroids or immunoglobulin raise the count within days. Immunoglobulin changes nothing in the marrow; a short steroid course rarely matters, but get the marrow within days if a lymphoid neoplasm is on the list.
no
2. Anything atypical? Another low lineage, monocytes, eosinophils, an odd smear, a big spleen, failure of everything?
yes
Marrow before the agonistAspirate and biopsy with flow cytometry, cytogenetics and a myeloid mutation panel. Hold the pill. Let the patient pick it up so there is no delay once the answer is in.
then
3. Marrow looks like immune thrombocytopenia?
yes
Start the agonistA thrombopoietin agonist is the second-line option after steroids, preferred over rituximab: eltrombopag or romiplostim (Neunert 2019), avatrombopag in the international consensus (Provan 2019). Weekly counts at first; the target is a safe count, not a normal one.
or
4. Marrow shows dysplasia, a monocytic clone, or a myeloid neoplasmThen the platelets were never immune. The agonist comes off the plan; the patient moves to the myeloid pathway (WHO 2022). Years of "refractory ITP" sometimes end this way.

Weekly blood counts in a patient who is not bleeding and not on a new drug tell you nothing you will act on. Count him when the plan changes.

Sources

Retrieved from PubMed, read on Oct 22, 2026.

  1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009. doi:10.1182/blood-2008-07-162503
  2. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011. doi:10.1182/blood-2010-08-302984
  3. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019. doi:10.1182/bloodadvances.2019000966
  4. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019. doi:10.1182/bloodadvances.2019000812
  5. Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009. doi:10.1182/blood-2009-05-224766
  6. Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study. Am J Hematol 2015. doi:10.1002/ajh.24011
  7. Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 2020. doi:10.1182/blood.2019003599
  8. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022. doi:10.1038/s41375-022-01613-1

Squamous cell carcinoma of the scalp, found late

A man kept a sore on his scalp under a cap for years. It was noticed during an admission for something else, called "infected", and treated with amoxicillin. Months later he arrives with a fungating tumor eroding the skull, a second ulcer behind it, and a firm nodule in front of the ear.

If you remember one thingA scalp cancer drains to the parotid, and the usual PET field stops at the skull base. Write "vertex to toes" on the order.

Concepts first

WHAT THE WORDS MEAN Cutaneous SCC squamous cell carcinoma of the skin: sun, age, immunity ultraviolet light leaves a high mutation load, so T cells can see the tumor once their brake, PD-1, is blocked (Migden 2018) Three states LOCALIZED surgery cures it LOCALLY ADVANCED surgery or radiation cannot cure it, or would cost too much function METASTATIC nodes (parotid, neck), distant T stage, head and neck skin T1 under 2 cm T2 2 to 4 cm T3 4 cm or more, minor bone erosion, nerve invasion, or deep (past the fat, or over 6 mm) T4a gross bone or marrow T4b skull base or foramina staging manual, 8th ed. (Lydiatt 2017) WHAT MAKES A SKIN SQUAMOUS CANCER DANGEROUS Thickness (Brantsch) 2 mm or less: none spread2 to 6 mm: 4% spreadover 6 mm: 16% spread Host immunosuppression,transplant, leukemia:4 times the risk Site and growth ear and lip, desmoplasticpattern, nerve invasion,recurrence after excision Field a scalp full of keratosesgrows the next tumor:examine the whole head

Where a scalp cancer goes, and where the scan must look

LYMPHATIC DRAINAGE OF THE SCALP foreheadvertextemple back parotid: the node to find occipital then the neck: upper levels from the parotid, posterior levels from the occiput THE PET SCAN FIELD skull base to mid-thigh the default request: the scalp is outside the box vertex to toes write it on the order for any scalp or skin primary

PET positron emission tomography with a glucose tracer; shows metabolically active tumor · vertex the top of the skull · PD-1 a brake on T cells; blocking it lets them attack the tumor · PD-L1 the tumor-side partner of PD-1

A nodule in front of the ear on a patient with a scalp cancer is a parotid node until the PET says otherwise.The parotid and upper neck nodes are where skin squamous cancer of the anterior scalp, temple and ear spreads first (Veness 2007); in Australian series metastatic skin cancer is the commonest parotid malignancy (O'Brien 2002). A parotid node moves the patient from locally advanced to regional disease, and it is the reason the systemic drug is not optional.

What the immunotherapy trials showed

RESPONSE IN SINGLE-ARM PHASE 2 TRIALS objective response: tumor shrinks 30% or more; pathologic complete response: no living tumor in the specimen cemiplimab, metastatic47% (28 of 59, Migden 2018) cemiplimab, locally advanced44% (34 of 78, Migden 2020) pembrolizumab, recurrent/metastatic35% (n = 105, Grob 2020; Hughes 2021) pembrolizumab, locally advanced50% (n = 54, Hughes 2021) neoadjuvant cemiplimab, 4 doses51% (40 of 79, Gross 2022) pathologic complete response: resectable stage II to IV (M0), up to four doses before surgery doses today: cemiplimab 350 mg every 3 weeks (trials above used 3 mg/kg every 2 weeks) pembrolizumab 200 mg every 3 weeks. No PD-L1 test is needed for either.

Tell the patient "about half" for cemiplimab and mean it. Pembrolizumab in recurrent or metastatic disease was closer to a third.Responses are durable: in the metastatic cohort, 82% of responders were still responding at data cutoff (Migden 2018), and that 82% is the number most often misremembered as the response rate. Median response duration was not reached in either pembrolizumab cohort (Hughes 2021).

Decide in clinic

1. Can a surgeon remove it with clear margins and acceptable function?
yes
Surgery, with radiation after if margins or nerves are involvedFor resectable stage II to IV disease, up to four doses of cemiplimab before surgery left no viable tumor in half the specimens (Gross 2022); discuss it with the surgeon before the first cut.
no
2. Not resectable, and no transplant or active autoimmune disease?
yes
Cemiplimab or pembrolizumab, nowStart with the pathology and clinical evidence of disease; staging refines the plan but does not need to delay the first dose. Hepatitis B and C, HIV and thyroid tests before the first infusion.
and
3. Bleeding, pain, odor, a fungating mass?
yes
Radiation to the primary, alongside the drugLocal control and hemostasis in weeks. Metronidazole gel on the wound for odor; tranexamic acid or hemostatic gauze with the home nurses; a bleeding plan for the family.
unless
4. Organ transplant recipientPD-1 blockade can reject the graft. Radiation, cetuximab, or chemotherapy, and a conversation with the transplant team before anything.

A draining, foul tumor is not an infection. If the discharge summary says amoxicillin, the diagnosis has not been made yet.

Sources

Retrieved from PubMed, read on Oct 22, 2026.

  1. Lydiatt WM, Patel SG, O'Sullivan B, et al. Head and neck cancers: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017. doi:10.3322/caac.21389
  2. Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008. doi:10.1016/S1470-2045(08)70178-5
  3. Veness MJ, Porceddu S, Palme CE, Morgan GJ. Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck 2007. doi:10.1002/hed.20576
  4. O'Brien CJ, McNeil EB, McMahon JD, et al. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck 2002. doi:10.1002/hed.10063
  5. Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018. doi:10.1056/NEJMoa1805131
  6. Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020. doi:10.1016/S1470-2045(19)30728-4
  7. Grob JJ, Gonzalez R, Basset-Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J Clin Oncol 2020. doi:10.1200/JCO.19.03054
  8. Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol 2021. doi:10.1016/j.annonc.2021.07.008
  9. Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med 2022. doi:10.1056/NEJMoa2209813

Small mediastinal nodes in a young adult with a cough

A woman in her twenties has had a dry cough for four months, with chills and fatigue in flares, and aching hips and hands. Chest CT: several small mediastinal nodes, normal hila, nothing in the lung. Blood counts and chemistry are normal. A close relative has sarcoidosis, found only after months of empirical tuberculosis treatment. She travels to histoplasma country: Mexico, Central America.

If you remember one thingFour doors: reactive, sarcoidosis, histoplasmosis, lymphoma. Blood opens one (histoplasma antigen and antibody), time opens one (repeat CT). The other two need the node, and the PET picks the node.

Concepts first

THE FOUR DOORS Reactive after an infection small, symmetric nodesno symptoms by then the test is time:repeat CT, 8 to 12 weeks four months of coughand chills is not"reactive" any more Sarcoidosis three things, all needed 1. a compatible picture2. a non-necrotizinggranuloma in tissue3. other causes excluded "never fully secure"(Crouser 2020) hilar nodes, skin, eyes,joints, calcium Histoplasmosis a fungus that mimics it river valleys of the US,Mexico, Central America antigen in urine, blood;antibodies take weeks(Wheat 2007; Azar 2017) granulomas look alike:fungal stains and cultureon every biopsy Lymphoma needs architecture a core or an excision,with flow cytometry a needle aspirate canconfirm granulomas butnot exclude lymphoma night sweats, weight loss,bulky nodes, high LDH A relative with sarcoidosis raises the odds, not the diagnosis siblings about 6 times, parents about 4 times the risk (Rybicki 2001); the tissue rule does not change

Getting the tissue

YIELD FOR GRANULOMAS IN SARCOIDOSIS WITH CHEST NODES (von Bartheld 2013) ultrasound-guided node aspiration80% bronchoscopy with lung biopsies53% 304 patients, 14 centers, randomized; serious complications 1 vs 2 ask for a core or extra passes when lymphoma is on the list What the PET adds picks the most active node for the needle, instead of the biggest finds a peripheral target: a neck node, skin, bone, spleen it cannot tell sarcoid from lymphoma

PET positron emission tomography, a glucose-tracer scan that lights up active tissue · EBUS endobronchial ultrasound, a bronchoscope with an ultrasound tip that guides a needle into nodes through the airway · LDH lactate dehydrogenase, a blood enzyme that rises with cell turnover and bulky lymphoma · stage I and II chest nodes alone, or nodes plus lung shadows

The angiotensin-converting enzyme does not make or break the diagnosis.The American Thoracic Society panel made one strong recommendation, baseline serum calcium in every diagnosed patient, and 13 conditional ones; none concerns the enzyme, which appears only as a "probable" supporting feature (Crouser 2020). A normal enzyme excludes nothing, and a high one proves nothing.

Decide in clinic

1. Red flags? Fever, night sweats, weight loss, nodes over 2 to 3 cm, cytopenias, high LDH
yes
Tissue now, core or excisionDo not wait for serology or a repeat scan. Flow cytometry on fresh tissue.
no
2. Lives in or traveled to histoplasma country?
yes
Histoplasma antigen in urine and serum, and antibodies, before the word sarcoid is writtenAdd interferon-gamma release assay for tuberculosis, HIV, calcium, and an autoimmune screen if the joints are involved. A positive here can end the workup.
then
3. Months of symptoms, small nodes, normal labs?
yes
PET to choose the target, then ultrasound-guided biopsyEndobronchial ultrasound for mediastinal nodes; a needle in a neck node or a skin lesion if the PET finds one. One procedure, every test: histology, flow cytometry, fungal and mycobacterial stains and cultures.
or
4. Well patient, nodes found by accident, nothing on serologyRepeat CT in 8 to 12 weeks is reasonable. What is not reasonable at any step: steroids before tissue. They blur the granulomas and feed the fungus.

The relative treated for tuberculosis for months had the biopsy at the end. The lesson is not "it was sarcoid". The lesson is that the biopsy should have been month one.

Sources

Retrieved from PubMed, read on Oct 22, 2026.

  1. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020. doi:10.1164/rccm.202002-0251ST
  2. von Bartheld MB, Dekkers OM, Szlubowski A, et al. Endosonography vs conventional bronchoscopy for the diagnosis of sarcoidosis: the GRANULOMA randomized clinical trial. JAMA 2013. doi:10.1001/jama.2013.5823
  3. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007. doi:10.1086/521259
  4. Azar MM, Hage CA. Laboratory diagnostics for histoplasmosis. J Clin Microbiol 2017. doi:10.1128/JCM.02430-16
  5. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001. doi:10.1164/ajrccm.164.11.2106001